SERCA2a gene transfer improves electrocardiographic performance in aged mdx mice

Jin-Hong Shin1, Brian Bostick, Yongping Yue

  • 1Department of Molecular Microbiology and Immunology, School of Medicine, The University of Missouri, Columbia, MO, USA.

Abstract

Insights

Gene therapy using adeno-associated virus (AAV) to over-express SERCA2a corrected heart rhythm abnormalities in a mouse model of Duchenne muscular dystrophy (DMD). This suggests a potential treatment for DMD-related heart disease.

Area of Science:

  • Cardiovascular Research
  • Gene Therapy
  • Muscular Dystrophy Research

Background:

  • Duchenne muscular dystrophy (DMD) is linked to heart problems caused by too much calcium in heart cells.
  • Sarcoplasmic reticulum calcium ATPase (SERCA2a) is crucial for managing calcium levels during heart relaxation.

Purpose of the Study:

  • To investigate if over-expressing SERCA2a can reduce electrocardiography (ECG) abnormalities in female mdx mice, a model for DMD cardiomyopathy.

Main Methods:

  • Female mdx mice received a single tail vein injection of adeno-associated virus serotype-9 (AAV-9) carrying the SERCA2a gene.
  • Cardiac function and ECGs were assessed eight months post-injection.

Main Results:

  • AAV-9 vector successfully delivered the SERCA2a gene to the heart, leading to its over-expression.
  • Mice treated with AAV-9 SERCA2a showed corrected ECG abnormalities, including heart rate, PR interval, and QT interval.

Conclusions:

  • Adeno-associated virus (AAV) mediated SERCA2a gene therapy shows promise for treating heart conditions in Duchenne muscular dystrophy.
  • This therapeutic approach may offer a new strategy for managing dystrophin-deficient heart disease.

Related Concept Videos